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Parkinson disease is the second most common neurodegenerative disease after Alzheimer disease, and
current demographic trends indicate a life-time risk approaching 4% and predict a doubling of prevalence by
2030. Strategies are being developed to apply recent advances in our understanding of the cause of
Parkinson disease to the development of biomarkers that will enable the identification of at-risk individuals,
enable early diagnosis and reflect the progression of disease. The latter will be particularly important for the
testing of disease-modifying therapies. This review summarizes recent advances in Parkinson disease
biomarker development.
Recent findings
Recent reports continue to reflect the application of a variety of clinical, imaging or biochemical measure-
ments, alone or in combination, to general Parkinson disease populations. Probably the most promising is the
assay of alpha-synuclein in the diagnosis and evolution of Parkinson disease. At present, detection techniques
are still being refined, but once accurate and reproducible assays are available, it will be important to define
the relationship of these to early diagnosis and progression. Alpha-synuclein concentrations may also be
modulated by certain disease-modifying agents in development and so may represent a measure of their
efficacy. It has to be accepted that no single measure currently fulfils all the necessary criteria for a biomarker
in Parkinson disease, but combinations of measures are more likely to deliver benefit.
Summary
The Parkinson disease biomarker field is approaching a stage when certain combinations of clinical,
imaging and biochemical measures may identify a proportion of individuals at risk for developing the
disease. However, their general applicability may be limited. Attention is now turning to stratification of
Parkinson disease into certain at-risk groups defined by genotype. The application of multimodal screening
to these populations may be more rewarding in the short term.
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KEY POINTS
 Current clinical markers are unlikely to prove sufficiently
specific on their own to qualify as biomarkers of
prodromal Parkinson disease.
 Biochemical fluid biomarkers related to pathogenesis,
for example alpha-synuclein and glucocerebrosidase,
offer the most promise for early diagnosis of
Parkinson disease.
 Biomarkers must reflect disease progression and the
potential for therapies to modify disease progress.
Movement disorders
396biomarker would need to reflect disease pro-
gression in a pathway targeted by the study
drug, or be a more general indicator of disease
progression.Currently, it seems unlikely that any single
evaluation will be capable of fulfilling any or all
of these roles, but the hope is that a combination
of biomarkers might achieve some.
The field of biomarkers in Parkinson disease has
attracted significant attention and there have been
numerous contributions to the field in the recent
past, and even since the most recent review of this
topic for Current Opinion in Neurology [1]. This review
will focus on only the most recent developments.
Most references are confined to 2011 and sub-
sequently, and the reader is referred to a number
of excellent reviews of this topic for additional
references [2
&
,3,4
&
,5,6].CLINICAL MARKERS
The motor features of Parkinson disease have
defined the disease and remain the most important
diagnostic marker [7]. However, there are some
important limitations to their application as a bio-
marker according to the requirements summarized
above. Bradykinesia, rigidity and tremor are thought
to appear only when the loss of dopaminergic
neurones is advanced, so they cannot be used as
an early marker. The motor features progress, but at
variable rates in different individuals [8]. Their
quantification is reasonably reproducible [9], but
may be limited by floor effects, especially in early
disease [10]. Although a reasonably accurate reflec-
tion of disability and response to symptomatic treat-
ment, motor features cannot be used as a marker of
disease modification if the interventional agent has
a symptomatic effect, unless a modified trial design
is used such as a delayed start.
Nonmotor clinical features are common in
Parkinson disease and may often arise even beforeright © Lippincott Williams & Wilkins. Unautho
www.co-neurology.commotor symptoms [11]. Thus, hyposmia, rapid eye
movement sleep behaviour disorder (RBD), depres-
sion, autonomic dysfunction and constipation have
all been linked to the clinical and pathological
evolution of Parkinson disease. The sensitivity,
specificity, positive and negative predicted values
of these clinical features have recently been
reviewed [3]. However, these nonmotor features
are a mixture of risk factors and biomarkers, the
former highlighting a symptom, sign or measure
that indicates the index individual is at a greater
risk of developing Parkinson disease than a con-
trol group without the corresponding feature(s),
whereas the latter is an objective measure, usually
directly related to pathogenesis.PATHOLOGICAL MARKERS
Recent data have drawn attention to the presence of
alpha-synuclein (SNCA) and Lewy bodies in the
gut of patients with Parkinson disease in biopsies
obtained several years before the onset of motor
features [12
&
]. This very important observation
requires confirmation with larger studies, but could
represent an interesting and relatively minimally
invasive technique for premotor assessment and
potentially as a marker for the efficacy of agents
designed to reduce SNCA levels that have access to
systemic tissues.IMAGING MARKERS
18-Fluoro-dopa positron emission tomography
(PET) or various dopamine presynaptic markers,
for example dopamine transporter (DAT) or vesicu-
lar monoamine transporter type 2, identified by
single photon emission tomography (SPECT), fulfil
many of the requirements of a useful marker of
Parkinson disease. They reflect the loss of nigro-
striatal dopamine neurons that cause the typical
early motor features of Parkinson disease. The scans
may be abnormal before the motor signs appear and
they progress as neurodegeneration continues.
However, the correlation with the Unified Parkin-
son Disease Rating Scale is limited, especially in the
early stages of the disease [13]. One study using
SPECT recently reported correlation of severity of
DAT deficit at baseline with progression of clinical
features over 22 months [14]. These imaging modal-
ities do not reliably distinguish between different
neurodegenerative parkinsonian syndromes, and
theymay bemodulated by dopaminergic drug inter-
ventions: levodopa causes a decline in both PET and
SPECT. Thus, they are considered of limited use as
markers, although are useful as diagnostic tools in
certain circumstances.rized reproduction of this article is prohibited.
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cardiac SPECT identifies postganglionic sympath-
etic denervation and is decreased in patients with
Parkinson disease and other synuclein diseases. It
can be an early indicator of catecholaminergic dys-
function.
Transcranial sonography (TCS) can reveal
increased echogenicity in up to 90% of patients with
clinical Parkinson disease. A recent prospective
study of asymptomatic individuals over 37 months
showed that 0.7% developed Parkinson disease and
the presence of nigral hyperechogenicity at baseline
increased the risk for Parkinson disease by 17-fold
[15]. However, TCS has limitations in terms of speci-
ficity and positive predictive value. Also, it is not
known what the hyperechogenicity reflects and it
does not seem to evolve or progress with disease.
Nevertheless, further work on TCS will be helpful, as
it is a noninvasive, cheap and accessible technique
that could find its value in combination with other
Parkinson disease markers.
Advanced techniques of MRI including diffu-
sion weighted imaging may be useful to identify a
proportion of patients with progressive supranu-
clear palsy or multiple system atrophy from Parkin-
son disease. High field strength magnetic resonance
and fractional anisotropy with diffusion tensor
imaging are under evaluation for the diagnosis of
Parkinson disease [16,17]. Reduced fractional aniso-
tropy in substantia nigra correlated with motor
severity and offers a particularly promising tool that
may correlate with disease progression. MRI tech-
niques to measure brain iron levels have shown
promise in their application to Parkinson disease.
A recent study [18] measured nigral (compacta and
reticulata) and caudate iron over 3 years and showed
accumulation in all these structures in patients with
Parkinson disease over time, which correlated with
motor progression.BIOCHEMICAL MARKERS
The development of biochemical markers for the
early diagnosis and progression of Parkinson disease
is most logically based on an understanding of
disease pathogenesis. Several pathogenetic pathways
are considered relevant includingmitochondrial dys-
function, oxidative stress, inflammation and protein
accumulation, aggregation and propagation [19,20].
The identification of prospective markers has also
been informed by advances in the genetics of Parkin-
son disease, for example the use of SNCA or DJ-1.Alpha-synuclein
SNCA expression and aggregation as Lewy bodies are
considered central to the pathogenesis of ParkinsonCopyright © Lippincott Williams & Wilkins. Unau
1350-7540  2013 Wolters Kluwer Health | Lippincott Williams & Wilkdisease. Thus, the detection of this protein may
enable correlation with the risk and progression of
the disease. SNCA may be transmitted between
neurons and so has access to the extracellular space,
although this may be in exosomes. SNCA has been
detected in plasma, saliva and cerebrospinal fluid
(CSF). There are significant issues relating to
the reproducibility of detection techniques from
different sources, but most have demonstrated a
reduction in SNCA in CSF in Parkinson disease
and other parkinsonian syndromes [21,22]. The
expression of data as a ratio of oligomeric to total
SNCA may be most valuable. In one analysis this
ratio reached 89.3% sensitivity and 90.6% speci-
ficity for Parkinson disease diagnosis [23]. Two
additional studies support the application of
the oligomer:total SNCA ratio [24,25]. Alternatively,
129-phosphorylation posttranslational modifica-
tion of SNCA, the most abundant form in Lewy
bodies, may be a useful target for detection [26].
The ratio of total SNCA with 129-phosphorylated
SNCA in CSF improved discrimination of Parkinson
disease from other parkinsonisms [27].
Why SNCA levels should be lower in Parkinson
disease CSF is not clear, butmay reflect alterations in
transcription, splicing or processing, or increased
clearance. The relationship of SNCA levels to the
stage of disease and its evolution over time, or the
effect of symptomatic therapies is not yet known.
The effects of therapies to influence SNCA expres-
sion and turnover, including immunotherapies
designed to reduce CNS SNCA, could in part be
informed by CSF SNCA levels.
SNCA and tau interact to promotemutual aggre-
gation. Thus, it has been suggested that simul-
taneous measurement of both proteins in CSF
may be of value in Parkinson disease. This is sup-
ported by recent data enabling the distinction of
synucleinopathies from other neurodegenerative
diseases [21,28].
Several studies have sought to measure SNCA in
blood cells, plasma and saliva, but the results have
been variable and, as with CSF studies, this probably
reflects the different assay techniques used.DJ-1
Mutations of DJ-1 are a rare cause of parkinsonism.
The full repertoire of functions of DJ-1 is unknown
but probably includes oxidant signalling with mito-
chondria. CSF and plasma levels of DJ-1 have been
found to be unaffected, elevated or more recently
reduced compared with controls [29,30]. There was
no correlation between CSF DJ-1 and fluoro-dopa
PET in eight patients with LRRK2 mutations com-
pared with controls [31].thorized reproduction of this article is prohibited.
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There has been a wide range of potential protein
markers investigated in Parkinson disease. These
include neurofilaments, interleukins, osteopontin
and hypocretin. However, results have been nega-
tive or inconclusive. A very recent study has
identified low levels of plasma ApoA1 as a sig-
nificant risk factor for Parkinson disease, and con-
centrations correlated with increased putaminal
loss on DAT scan [32
&&
]. ApoA1 is a major com-
ponent of high-density lipoprotein (HDL), and it is
of note that statin use, which increases HDL, is
associated with a reduced risk for Parkinson dis-
ease [33].
CSF amyloid-beta(1–42) levels have been
studied to determine whether they reflect the risk
for dementia in Parkinson disease. In Alzheimer
disease, there is an increase in CSF total tau and
phosphorylated tau, with a reduction in amyloid-
beta(1–42). In Parkinson disease, however, tau
levels appear unchanged with only a small decrease
in amyloid levels [34]. However, there is interest in
using amyloid levels and tau ratios to predict cog-
nitive decline in Parkinson disease [35–39]. Low
levels of plasma epidermal growth factor have been
reported to correlate with cognitive function in
Parkinson disease and to be a marker for future
cognitive decline [40].
Urate is an antioxidant and studies have shown
that the risk of Parkinson disease is inversely pro-
portional to plasma urate [41,42], and levels are
lower in patients with Parkinson disease [43]. How-
ever, its use as a diagnostic marker in isolation is
limited.STRATIFICATION OF PARKINSON
DISEASE
Parkinson disease has multiple causes and so the
biomarker studies performed to date have almost
all been on a heterogeneous population in aetio-
logical terms. This inevitably limits the performance
of biomarkers related to specific pathogenetic
pathways. However, the identification of certain
genetic causes of Parkinson disease has enabled the
characterizsation of specific more homogeneous
subgroups. These include those with LRRK2
mutations, who represent approximately 0.5–1.0%
of unselected Parkinson disease cases in the general
western communities, although considerably greater
proportions of familial Parkinson disease or those of
Ashkenazi Jewish origin. Studies are currently under-
way to determine whether there are specific bio-
chemical or imaging profiles that reflect disease
expression and progression in both LRRK2 Parkinson
disease patients and asymptomatic carriers. Ofopyright © Lippincott Williams & Wilkins. Unautho
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LRRK2 Parkinson disease may also be applicable to
non-LRRK2 Parkinson disease.
Patients with mutations of the glucocerebrosi-
dase (GBA) gene represent the largest identifiable
group of individuals at risk for Parkinson disease.
The precise risk for Gaucher disease patients devel-
oping Parkinson disease is not known, but has been
variously estimated as 20–30 fold [44,45]. Con-
versely, 5–10% of patients with Parkinson disease
have GBA mutations, making these mutations
numerically the most important risk factor for the
disease identified to date. Parkinson disease associ-
ated with GBA mutations (GBA-PD) is clinically,
pathologically and pharmacologically indistin-
guishable from idiopathic ‘sporadic’ Parkinson dis-
ease, although GBA-PD has a slightly earlier onset
(5 years) and rather more frequent cognitive dys-
function. Recent studies demonstrating a reciprocal
relationship between SNCA and the GBA enzyme
(glucocerebrosidase) are of considerable importance
to our understanding of the pathogenesis of GBA-PD
and idiopathic Parkinson disease [46,47]. The patho-
genesis of the neurodegeneration in this group in
this group appears to mirror pathways identified in
non-GBA positive Parkinson disease, including
mitochondrial dysfunction and oxidative stress
[48] and lysosomal dysfunction [49]. Thus, they
represent a large cohort not only for which specific
therapiesmay be applicable [50] but also for detailed
analysis for biomarkers within the lysosomal path-
ways that may be applicable to the general Parkin-
son disease population.OMICS
The investigation of biological specimens for bio-
chemical profiles is entering a new era with the
application of novel technologies capable of mass
analyses. These include transcriptomics, proteomics
and metabolomics. These powerful tools have the
capacity to identify small changes inmRNA, protein
or metabolite profiles between different cohorts and
can be applied to tissue, cells or fluids [51]. Although
powerful techniques, there remain issues with
reproducibility of data. In part, this is likely to
reflect the problem with population heterogeneity
described above. A single biochemical profile is
unlikely to reflect a complex disease process that
may well evolve over time and be different between
aetiological groups. Perhaps themost effective use of
these technologies in the first instance will be their
applicability to stratified groups of patients with
Parkinson disease, with subsequent evaluation of
any promising profiles in the general Parkinson
disease population.rized reproduction of this article is prohibited.
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There is a general consensus that it is unlikely that
one single measure will faithfully reflect the com-
plex pathological processes that underlie the devel-
opment, expression and progression of Parkinson
disease. It is muchmore likely that a combination of
markers will be required and this may include
clinical, for example olfactory function, bio-
chemical and imaging markers to define at-risk
individuals, early Parkinson disease diagnosis and
progression. There have, of course, already been a
number of attempts to do this particularly using
clinical parameters, for example olfactory function,
sleep behaviour and imaging in both general Parkin-
son disease populations [52,53] and genetically
defined populations [54]. Multiple CSF markers
have been analysed to differentiate Parkinson dis-
ease from other parkinsonian syndromes, dementia
with Lewy bodies, Parkinson disease with dementia
and Alzheimer disease, with some success [30,55].
The PARS (Parkinson At-Risk Syndrome study)
has recruited 4999 patients with Parkinson disease
who returned a screening olfaction test and ques-
tionnaire, and 669 were at or below the 15th centile
for olfaction [56
&
]. Hyposmia aggregated with other
nonmotor features. This study involves an imaging
arm and represents an important development in
risk assessment and early clinical features for
Parkinson disease.PRACTICAL USE OF BIOMARKERS IN
PARKINSON DISEASE: A PERSONAL VIEW
It is often recited that even an early clinical diag-
nosis of Parkinson disease is made at a time of
advanced nigral neurodegeneration. This is true,
and indeed the rate of early loss of motor function
that follows is rapid. It stands to reason that any
disease-modifying agent with neuroprotective or
neurorescue properties [57] will have most chance
of success if given at the earliest period in the
evolution of the neurodegenerative process [58].
However, an opportunity to slow or halt progression
even at the time of Parkinson disease diagnosis
would leave patients substantially improved over
time. Thus, although earlier (premotor) diagnosis
is a laudable goal, the more pragmatic view is to
have a marker of disease progression against
whichputativeneuroprotectiveordisease-modifying
agents may be tested. This would represent a major
advance in Parkinson disease research. Of course,
these two ambitions are not mutually exclusive.CONCLUSION
The search for an appropriate biomarker for Parkin-
son disease continues. It is increasingly unlikely thatCopyright © Lippincott Williams & Wilkins. Unau
1350-7540  2013 Wolters Kluwer Health | Lippincott Williams & Wilkany single measure will suffice, at least in the fore-
seeable future, and that a combination of measures
will be required. Pragmatically, the most critical
attribute for a biomarker is not that it diagnoses
Parkinson disease early, before motor features
appear, but rather that it reflects a pathogenetic
process and progression of the disease against which
potential disease-modifying agents may be judged.
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